[1] D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol, 2006, 44:217-231.
[2] Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol, 2006, 4:1385-1394.
[3] D’Amico G, Perricone G. Prediction of decompensation in patients with compensated cirrhosis: Does Etiology Matter? Curr Hepatol Rep, 2019, 18:144-156.
[4] D'Amico G, Villanueva C, Burroughs A, et al. Clinical stages of cirrhosis a multicenter study of 1858 patients. Hepatology, 2010, 52(S1):329A.
[5] Zipprich A, Garcia-Tsao G, Rogowski S, et al. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int, 2012, 32:1407-1414.
[6] Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology, 2010, 51:1675-1682.
[7] D'Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther, 2014, 39:1180-1193.
[8] Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology, 2010, 139:1246-1256, 1256.e1241-1245.
[9] Fede G, D'Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol, 2012, 56:810-818.
[10] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology, 2013, 144:1426-1437, 1437.e1421-1429.
[11] Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol, 2014, 60:1310-1324.
[12] Villanueva C, Albillos A, Genescà J, et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. J Hepatol, 2021, 75:589-599.
[13] Gustot T, Fernandez J, Garcia E, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology, 2015, 62:243-252.
[14] Domenicali M, Baldassarre M, Giannone FA, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology, 2014, 60:1851-1860.
[15] Trebicka J, Amoros A, Pitarch C, et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis. Front Immunol, 2019, 10:476.
[16] Jalan R, Pavesi M, Saliba F, et al. The CLIF consortium acute decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol, 2015, 62:831-840.
[17] Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol, 2020, 73:842-854.
[18] Trebicka J, Fernandez J, Papp M, et al. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol, 2021, 74:1097-1108.
[19] Piano S, Tonon M, Vettore E, et al. Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol, 2017, 67:1177-1184.
[20] Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol, 2004, 40:823-830.
[21] Wiegand J, Kühne M, Pradat P, et al. Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis. Aliment Pharmacol Ther, 2012, 35:1443-1450.
[22] Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharmacol Ther, 2020, 51:64-77.
[23] Lens S, Baiges A, Alvarado-Tapias E, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol, 2020, 73:1415-1424.
[24] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, 2018, 391:2417-2429. |
